Moderna and ROVI Expand Long-term Collaboration for the Manufacture of MRNA Medicines Over the Next Ten Years
Long-term agreement includes a series of investments to acquire new equipment and adapt the present ROVI drug product fill-finish facilities and production lines in Spain CAMBRIDGE, MA and MADRID, SPAIN...
Moderna Announces Additional Investments to Increase Global Supply for COVID-19 Vaccine to up to 3 Billion Doses in 2022
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it is making new funding commitments to increase supply at its owned and...
Moderna and ROVI Announce Collaboration for OUS Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate
Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines, and Laboratorios Farmacéuticos...